VIOLIN Logo
Cov19VaxKB Banner
Search: for Help
Cov19VaxKB Home
Introduction
Statistics
Cov19VaxKB Query
Phase III
Phase II
Phase I
Preclinical
Cov19Vax Safety
Cov19Vax Design
Cov19Vax News
Data Submission
Data Exchange
Data Download
Links
Documentation
Cov19VaxKB Updates
Acknowledgements
FAQs
Disclaimer
Contact Us
UMMS Logo

Phase III COVID-19 Vaccines

This site collects existing Phase III COVID-19 vaccines around the world as of November 28, 2020.

Existing vaccines in Phase III clinical trials include:

  1. Ad26.COV2.S
    • Other names: JNJ-78436735
    • Clinical trial ID:
      • Phase III: NCT04505722 (protocol)
        • Age subgroups: 18-59 years; 60 years and above
        • Location: USA, Argentina, Brazil, Chile, Colombia, Mexico, Peru, Philippines, South Africa, Ukraine
      • Phase III: NCT04614948
        • Age subgroups: 18 years and above
        • Location: USA, Belgium, Colombia, France, Germany, Philippines, South Africa, Spain, UK
    • Type: Recombinant vector vaccine
    • Manufacturer: Janssen Pharmaceutica
    • Publications:
      • Bos et al. Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responses. NPJ Vaccines. 2020; 5; 91. [PubMed: 33083026].
      • Mercado et al. Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques. Nature. 2020; ; . [PubMed: 32731257].
    • VIOLIN: 5782
    • VO: VO_0005159
  2. Ad5-nCoV vaccine
    • Clinical trial ID:
      • Phase III: NCT04526990
        • Age subgroups: 18 years and above
        • Location: Argentina, Chile, Mexico, Pakistan, Russia
      • Phase III: NCT04540419
        • Age subgroups: Healthy adults aged 18-85 years
        • Location: Russia
      • Phase II: NCT04341389 (protocol)
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: China
    • Type: Recombinant vector vaccine
    • Manufacturer: CanSino Biologics
    • Publications:
      • Zhu et al. Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020; 396(10249); 479-488. [PubMed: 32702299].
      • Zhu et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet. 2020; 395(10240); 1845-1854. [PubMed: 32450106].
    • VIOLIN: 5768
    • VO: VO_0005144
  3. AZD1222
    • Other names: ChAdOx1 nCoV19 vaccine
    • Clinical trial ID:
      • Phase III: NCT04516746 (protocol)
        • Age subgroups: 18-64 years; 65 years and above
        • Location: USA, Argentina, Chile, Colombia, Peru
      • Phase III: NCT04540393
        • Age subgroups: 18 years and above
        • Location: Russia
      • Phase III: NCT04536051
        • Age subgroups: 18-55 years; 56-69 years; 70 years and above
        • Location: Brazil
      • Phase III: ISRCTN89951424
        • Age subgroups: 18-55 years
        • Location: Brazil
      • Phase III: CTRI/2020/08/027170
        • Age subgroups: 18 years and above
        • Location: India
    • Type: Recombinant vector vaccine
    • Manufacturer: AstraZeneca
    • Publications:
      • Folegatti et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. Lancet. 2020; 396(10249); 467-478. [PubMed: 32702298].
    • VIOLIN: 5774
    • VO: VO_0005158
  4. BBIBP-CorV
    • Clinical trial ID:
      • Phase III: NCT04560881
        • Age subgroups: 18-85 years
        • Location: Argentina
      • Phase III: ChiCTR2000034780
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: UAE
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Beijing Institute of Biological Products; Sinopharm
    • Publications:
      • Wang et al. Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2. Cell. 2020;182(3); 713-721. [PubMed: 32778225].
    • VIOLIN: 5776
    • VO: VO_0005166
  5. BNT162 vaccine
    • Clinical trial ID:
      • Phase I/II/III: NCT04368728 (protocol)
        • Age subgroups:
          • Phase I: 18-55 years; 65-85 years
          • Phase II/III: 12-15 years; 16-55 years; 56 years and above  
        • Location: USA, Argentina, Brazil, Germany, South Africa, Turkey
    • Type: mRNA vaccine
    • Manufacturer: BioNTech; Pfizer
    • Publications:
      • Walsh et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020; ; . [PubMed: 33053279].
      • Sahin et al. COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T-cell responses. Nature. 2020; ; . [PubMed: 32998157].
      • Mulligan et al. Phase 1/2 study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020; ; . [PubMed: 32785213].
    • VIOLIN: 5784
  6. COVAXIN
    • Other names: BBV152
    • Clinical trial ID:
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Bharat Biotech
  7. COVID-19 inactivated virus vaccine by Wuhan Institute of Biological Products
    • Clinical trial ID:
      • Phase III: ChiCTR2000034780
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: UAE
      • Phase III: ChiCTR2000039000
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: Morocco
      • Phase III: NCT04612972
        • Age subgroups: Healthy adults aged 18 years and above
        • Location: Peru
      • Phase I/II: ChiCTR2000031809 (protocol)
        • Age subgroups: 6 years and above
        • Location: China
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Wuhan Institute of Biological Products; Sinopharm
    • Publications:
      • Xia et al. Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes: Interim Analysis of 2 Randomized Clinical Trials. JAMA. 2020; 324(10); 1–10. [PubMed: 32789505].
    • VIOLIN: 5775
    • VO: VO_0005160
  8. CoVLP
    • Clinical trial ID:
      • Phase II/III: NCT04636697
        • Age subgroups: 18-64 years; 65 years and above
        • Location: Canada
    • Type: Virus-like particle
    • Manufacturer: Medicago Inc.
  9. Gam-COVID-Vac
    • Other names: Sputnik V
    • Clinical trial ID:
      • Phase III: NCT04530396
        • Age subgroups: 18-30; 31-40; 41-50; 51-60; 61 years and above
        • Location: Russia
      • Phase III: NCT04564716
        • Age subgroups: 18-60 years
        • Location: Belarus
    • Type: Recombinant vector vaccine
    • Manufacturer: Gamaleya Research Institute
    • Publications:
      • Logunov et al. Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia. Lancet. 2020; 396(10255); 887-897. [PubMed: 32896291].
    • VIOLIN: 5777
    • VO: VO_0005163
  10. mRNA-1273 vaccine
    • Clinical trial ID:
      • Phase III: NCT04470427 (protocol)
        • Age subgroups: 18-64 years; 65 years and above
        • Location: USA
    • Type: mRNA vaccine
    • Manufacturer: Moderna
    • Publications:
      • Anderson et al. Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults. N Engl J Med. 2020; ; . [PubMed: 32991794].
    • VIOLIN: 5789
    • VO: VO_0005157
  11. NVX-CoV2373
    • Clinical trial ID:
      • Phase III: NCT04583995 (protocol)
        • Age subgroups: 18-64 years; 65-84 years
        • Location: UK
      • Phase III: NCT04611802
        • Age subgroups: 18 years and above
        • Location: USA, Mexico, Puerto Rico
    • Type: Nanoparticle vaccine
    • Manufacturer: Novavax
    • Publications:
      • Keech et al. Phase 1-2 Trial of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine. N Engl J Med. 2020; ; . [PubMed: 32877576].
    • VIOLIN: 5791
    • VO: VO_0005155
  12. PiCoVacc
    • Other names: CoronaVac
    • Clinical trial ID:
      • Phase III: NCT04456595 (protocol)
        • Age subgroups: 18-59 years; 60 years and above
        • Location: Brazil
      • Phase III: 669/UN6.KEP/EC/2020
        • Age subgroups: Clinically healthy adults aged 18-59 years
        • Location: Indonesia
      • Phase III: NCT04582344
        • Age subgroups: Healthy adults aged 18-59 years
        • Location: Turkey
      • Phase III: NCT04617483
        • Age subgroups: 18-25 years; 26-45 years; 46-59 years; 60 years and above
        • Location: China
    • Type: Inactivated or “killed” vaccine
    • Manufacturer: Sinovac
    • Publications:
      • Gao et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science (New York, N.Y.). 2020; 369(6499); 77-81. [PubMed: 32376603].
    • VIOLIN: 5761
    • VO: VO_0005141

Provenance: All data in Cov19VaxKB originates from manual curation of reliable resources.

Note: The page was updated on November 28, 2020. We plan to update this page on a weekly or even a daily basis. Please provide us with any new information that you believe would be useful if included on the website.